Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by ifsoon May 07, 2016 11:14pm
263 Views
Post# 24851434

RE:RE:RE: Compassionate use plaminogen

RE:RE:RE: Compassionate use plaminogenI do believe that this patient saw other improvements in his health condition, as he had other complications caused by his plasminogene deficiency. What were the complications he had? What was found out? It's only my intuition, nothing proved to me except for the fingers, but I think what the pictures show us is only part of the story...

From the link Gerry gave us:
"Other medical complications caused by the patient's plasminogen deficiency made him unable to travel to participate in ProMetic's ongoing Phase 2/3 plasminogen deficiency clinical trial.  Therefore he was treated under an Expanded Access protocol, enabling him to receive a similar treatment regimen to that used in the Phase 2/3 trial"

https://www.newswire.ca/news-releases/prometic-announces-successful-treatment-of-a-plasminogen-deficient-patient-under-an-expanded-access-compassionate-use-protocol-in-the-usa-577922271.html

Thanks Gerry



Bullboard Posts